Schaffen Pharma: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
Schaffen Pharma
Largest movements
- Receivables within one year -€11,912
down €11,912 (-14.7%), from €81,083 to €69,171
of which Other amounts receivable: -€30,000
- Cash +€9,490
up €9,490 (+20.6%), from €46,048 to €55,538
mainly Other debts (+€41,078) and Receivables within one year (+€11,912)
- Tangible fixed assets -€6,949
down €6,949 (-16.8%), from €41,265 to €34,316
of which Other tangible fixed assets: -€4,566
- Stocks and contracts -€2,735
down €2,735 (-3.3%), from €82,819 to €80,084
- Other debts +€41,078
up €41,078 (+319.4%), from €12,862 to €53,940
- Profit (loss) carried forward -€38,596
down €38,596, from €23,541 to -€15,055
- Trade debts -€25,380
down €25,380 (-30.4%), from €83,588 to €58,208
- Tax, wage and social debts +€10,596
new in 2025: €10,596
- Staff costs +€37,854
up €37,854 (+66.0%), from €57,374 to €95,228
- Gross operating margin +€35,640
up €35,640 (+118.6%), from €30,042 to €65,682
- Financial charges +€758
up €758 (+51.6%), from €1,470 to €2,228
- Other operating charges +€678
up €678 (+574.3%), from €118 to €796
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €258,474 | €246,323 | -€12,150 | -4.7% |
| Fixed assets | 21/28 | €41,265 | €34,316 | -€6,949 | -16.8% |
| Tangible fixed assets | 22/27 | €41,265 | €34,316 | -€6,949 | -16.8% |
| Plant, machinery and equipment | 23 | €3,101 | €718 | -€2,383 | -76.8% |
| Other tangible fixed assets | 26 | €38,165 | €33,598 | -€4,566 | -12.0% |
| Current assets | 29/58 | €217,209 | €212,007 | -€5,202 | -2.4% |
| Stocks and contracts in progress | 3 | €82,819 | €80,084 | -€2,735 | -3.3% |
| Stocks | 30/36 | €82,819 | €80,084 | -€2,735 | -3.3% |
| Amounts receivable within one year | 40/41 | €81,083 | €69,171 | -€11,912 | -14.7% |
| Trade receivables | 40 | €42,611 | €60,699 | +€18,088 | +42.4% |
| Other amounts receivable | 41 | €38,472 | €8,472 | -€30,000 | -78.0% |
| Cash at bank and in hand | 54/58 | €46,048 | €55,538 | +€9,490 | +20.6% |
| Deferred charges and accrued income | 490/1 | €7,259 | €7,214 | -€44 | -0.6% |
| Total equity and liabilities | 10/49 | €258,474 | €246,323 | -€12,150 | -4.7% |
| Equity | 10/15 | €162,000 | €123,404 | -€38,596 | -23.8% |
| Contributions | 10/11 | €18,550 | €18,550 | = | 0.0% |
| Reserves | 13 | €119,909 | €119,909 | = | 0.0% |
| Non-distributable reserves | 130/1 | €1,855 | - | -€1,855 | |
| Reserves not available under the articles | 1311 | €1,855 | - | -€1,855 | |
| Distributable reserves | 133 | €118,054 | €119,909 | +€1,855 | +1.6% |
| Profit (loss) carried forward | 14 | €23,541 | -€15,055 | -€38,596 | |
| Amounts payable | 17/49 | €96,474 | €122,920 | +€26,446 | +27.4% |
| Amounts payable within one year | 42/48 | €96,450 | €122,744 | +€26,294 | +27.3% |
| Trade debts | 44 | €83,588 | €58,208 | -€25,380 | -30.4% |
| Suppliers | 440/4 | €83,588 | €58,208 | -€25,380 | -30.4% |
| Taxes, remuneration and social security | 45 | - | €10,596 | +€10,596 | |
| Remuneration and social security | 454/9 | - | €10,596 | +€10,596 | |
| Other amounts payable | 47/48 | €12,862 | €53,940 | +€41,078 | +319.4% |
| Accrued charges and deferred income | 492/3 | €24 | €176 | +€152 | +633.3% |
| Remuneration, social security and pensions | 62 | €57,374 | €95,228 | +€37,854 | +66.0% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €6,949 | €6,949 | = | 0.0% |
| Other operating charges | 640/8 | €118 | €796 | +€678 | +574.3% |
| Gross operating margin | 9900 | €30,042 | €65,682 | +€35,640 | +118.6% |
| Operating profit (loss) | 9901 | -€34,399 | -€37,291 | -€2,891 | -8.4% |
| Financial income | 75/76B | €1,114 | €923 | -€191 | -17.1% |
| Recurring financial income | 75 | €1,114 | €923 | -€191 | -17.1% |
| Financial charges | 65/66B | €1,470 | €2,228 | +€758 | +51.6% |
| Recurring financial charges | 65 | €1,470 | €2,228 | +€758 | +51.6% |
| Profit (loss) for the period before taxes | 9903 | -€34,756 | -€38,596 | -€3,840 | -11.0% |
| Profit (loss) for the period | 9904 | -€34,756 | -€38,596 | -€3,840 | -11.0% |
| Profit (loss) for the period to be appropriated | 9905 | -€34,756 | -€38,596 | -€3,840 | -11.0% |
Source: filed annual accounts (NBB), fiscal years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 9 October 2026 via checked.be.